As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Dr. Bogenschutz presents quantitative findings from a psilocybin trial for alcohol use disorder, showing reduced alcohol craving and improved mood and cognition. Dr. Agin-Liebes discusses qualitative results on self-awareness and
Gabrielle Agin-Liebes
Psychedelic-assisted therapy's history, Bill W's admiration, and the need for peer support group understanding are discussed in relation to sobriety, recovery, and psychedelics.
Kevin Franciotti, Reilly Capps, Celeste Alvarez, Danielle Nova, Rick Barnett, Juliana Mulligan
Overview of a multicenter trial compares psilocybin therapy to active control for demoralization in end-of-life adults. Trial focuses on treating depression, anxiety, and improving quality of life, spiritual well-being, and
Jessi Humphreys
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby
Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case
Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper
Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.
Philippe Lucas
Study investigates psilocybin's effects on depression and burnout in healthcare clinicians post-COVID frontline work with pre- and post-dose psychotherapy. Trial registration: NCT05163496.
Anthony L Back
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins
Psilocybin trial for advanced cancer patients will compare effects of 25mg dose to 1mg placebo on anxiety, depression, and existential distress, using psychotherapy to assess efficacy and psychological mechanisms.